Facebook
Twitter
Telegram
Report an ErrorPieris Pharmaceuticals Balance Sheet 2011-2024 | PIRS
Annual Balance Sheet Pieris Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-26.4 M | -104 M | -70.4 M | -46 M | -74.9 M | -37.9 M | -29.4 M | -29.3 M | -10.7 K | -4.73 K | - | - | |
Long Term Debt |
- | 12.2 M | 13.8 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | 859 K | - | 1.03 M | 733 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 6 K | 62.7 M | 53.3 M | 46.6 M | 1.46 M | 23.9 K | - | - | - | - |
Total Current Liabilities |
11.9 M | 36.6 M | 50.6 M | 22.1 M | 27 M | 48.1 M | 45.8 M | 8.38 M | 2.8 M | 3.54 M | - | - | - |
Total Liabilities |
11.9 M | 67.6 M | 103 M | 74 M | 89.7 M | 101 M | 92.4 M | 9.84 M | 2.82 M | 1.12 K | 474 | - | - |
Deferred Revenue |
- | 20.8 M | 25.1 M | 12.6 M | 11.3 M | 35.6 M | 37.2 M | 2.27 M | - | - | - | - | - |
Retained Earnings |
-315 M | -290 M | -257 M | - | -174 M | -147 M | -120 M | -103 M | -79.9 M | -16 K | -274 | - | - |
Total Assets |
38.7 M | 95.5 M | 154 M | 105 M | 141 M | 141 M | 104 M | 35.1 M | 34 M | 11.1 K | 5.2 K | - | - |
Cash and Cash Equivalents |
17.4 M | 38.6 M | 118 M | 70.4 M | 62.3 M | 74.9 M | 37.9 M | 29.4 M | 29.3 M | 18.5 M | 3.69 M | - | - |
Book Value |
26.8 M | 27.9 M | 50.8 M | 31 M | 51.4 M | 39.9 M | 11.5 M | 25.2 M | 31.1 M | 10 K | 4.73 K | - | - |
Total Shareholders Equity |
26.8 M | 27.9 M | 50.8 M | 31 M | 51.4 M | 39.9 M | 11.5 M | 25.2 M | 31.1 M | 18 M | 585 K | - | - |
All numbers in USD currency
Quarterly Balance Sheet Pieris Pharmaceuticals
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 11.9 M | - | 12.2 M | 11.4 M | - | 13.4 M | 13.8 M | 14.4 M | 15 M | 15 M | 15.9 M | 15.9 M | 15.9 M | 15.9 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | 28.9 M | 47 M | - | 67.6 M | 63.4 M | - | 83.7 M | 103 M | 110 M | 108 M | 77.6 M | 74 M | 74 M | 74 M | 74 M | 89.7 M | 89.7 M | 89.7 M | 89.7 M | 101 M | 101 M | 101 M | 101 M | 92.4 M | 92.4 M | 92.4 M | 92.4 M | 9.84 M | 9.84 M | 9.84 M | 9.84 M | 2.82 M | 2.82 M | 2.82 M | 2.82 M | 3.85 M | 3.88 M | 3.88 M | 3.88 M | 6.69 M | 474 | 3.32 K | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 994 K | 17.7 M | - | 20.8 M | 18.5 M | - | 20.9 M | 25.1 M | 26.4 M | 25.5 M | 17.2 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 35.6 M | 31.9 M | 44.6 M | 46.3 M | 37.2 M | 37.2 M | 37.2 M | 37.2 M | 2.28 M | 2.27 M | 2.27 M | 2.27 M | - | - | - | - | - | - | - | - | 545 K | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-320 M | -315 M | -310 M | -300 M | - | -290 M | -282 M | - | -262 M | -257 M | -248 M | -231 M | -216 M | -211 M | -211 M | -211 M | -211 M | -174 M | -174 M | -174 M | -174 M | -147 M | -147 M | -147 M | -147 M | -120 M | -120 M | -120 M | -120 M | -103 M | -103 M | -103 M | -103 M | -79.9 M | -79.9 M | -79.9 M | -79.9 M | -65.8 M | -65.8 M | -65.8 M | -65.8 M | -56 M | -274 | -8.23 K | - | - | - | - | - | - | - | - | - |
Total Assets |
29.5 M | 38.7 M | 59.4 M | 87.5 M | - | 95.5 M | 99.2 M | - | 137 M | 154 M | 164 M | 155 M | 116 M | 105 M | 105 M | 105 M | 105 M | 141 M | 141 M | 141 M | 141 M | 141 M | 141 M | 141 M | 141 M | 104 M | 104 M | 104 M | 104 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 34 M | 34 M | 34 M | 34 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 7.28 M | 5.2 K | 90 | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
19.1 M | 17.4 M | 32.9 M | 44.9 M | - | 38.6 M | 48.4 M | - | 83.7 M | 118 M | 125 M | 119 M | 66.8 M | 70.4 M | 70.4 M | 70.4 M | 70.4 M | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 74.9 M | 74.9 M | 74.9 M | 74.9 M | 37.9 M | 37.9 M | 37.9 M | 37.9 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.3 M | 29.3 M | 29.3 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 3.69 M | 90 | 90 | - | 6.33 M | - | - | - | - | - | - | - |
Book Value |
- | - | 30.5 M | 40.5 M | - | 27.9 M | 35.8 M | - | 53.4 M | 50.8 M | 53.9 M | 46.7 M | 38.2 M | 31 M | 31 M | 31 M | 31 M | 51.4 M | 51.4 M | 51.4 M | 51.4 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 18 M | 18 M | 18 M | 18 M | 585 K | 4.73 K | -3.23 K | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
22 M | 26.8 M | 30.5 M | 40.5 M | 15.5 M | 27.9 M | 35.8 M | - | 53.4 M | 50.8 M | 53.9 M | 46.7 M | 38.2 M | 31 M | 31 M | 31 M | 31 M | 51.4 M | 51.4 M | 51.4 M | 51.4 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 18 M | 18 M | 18 M | 18 M | 585 K | 4.73 K | 4.73 K | - | 496 K | - | - | - | - | - | - | - |
All numbers in USD currency